The earnings call highlighted strong revenue growth and recovery post-drug shortage, along with positive R&D developments. However, challenges such as the previous drug shortage's financial impact and declining Trogarzo sales indicate a cautious business outlook.

Company Guidance -

Q3 2025

During the Theratechnologies First Quarter 2025 Earnings Call, the company provided guidance for the fiscal year, projecting total revenues of $80 to $83 million and an adjusted EBITDA of $10 to $12 million. Despite a temporary drug shortage impacting EGRIFTA SV sales for six to seven weeks, the company reported $19 million in total revenues for the quarter, marking a 17% increase year-over-year. Adjusted EBITDA for the quarter was $2.3 million, compared to a loss of $247,000 in the previous year. The company also discussed the successful rebound in patient enrollments, which were up 15% in the first quarter compared to last year. Additionally, they highlighted the recent approval of the F8 Formulation of Tesamorelin and the anticipated transition from EGRIFTA SV to EGRIFTA WR, expected to be completed by early 2026.

Revenue Growth

Total revenues increased to $19 million, representing a 17% growth from the previous year, driven by strong performance of EGRIFTA SV.

EGRIFTA SV Recovery and Transition Plan

Following a drug shortage, EGRIFTA SV resumed distribution, with new enrollments up 15% in Q1 compared to last year. The transition to the new F8 formulation is planned for completion by early 2026.

Positive Adjusted EBITDA

The company reported a positive adjusted EBITDA of $2.3 million, up from a loss of $247,000 last year.

New Formulation Approval

Approval of the F8 Formulation of Tesamorelin, which requires less frequent reconstitution and is expected to improve patient adherence and experience.

Research and Development Progress

Data from the PROMISE-U.S. and VAMOS studies presented, highlighting the efficacy and safety of ibalizumab and the importance of EVAF in cardiovascular risk assessment in HIV patients.

Theratechnologies (THTX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

THTX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 09, 2025	2025 (Q3)	0.01 / -	0.06	―	―	―
Jul 09, 2025	2025 (Q2)	-0.01 / -0.09	0.02	-550.00% (-0.11)	―	―
Apr 09, 2025	2025 (Q1)	0.03 / 0.00	-0.1	―	―
Feb 26, 2025	2024 (Q4)	0.05 / -0.16	-0.08	-100.00% (-0.08)	―
Oct 10, 2024	2024 (Q3)	0.03 / 0.06	-0.03	300.00% (+0.09)	―
Jul 10, 2024	2024 (Q2)	-0.02 / 0.02	-0.405	104.94% (+0.43)	―
Apr 10, 2024	2024 (Q1)	-0.12 / -0.10	-0.44	77.27% (+0.34)	―
Feb 21, 2024	2023 (Q4)	-0.31 / -0.08	-0.36	77.78% (+0.28)	―
Sep 26, 2023	2023 (Q3)	-0.29 / -0.03	-0.32	90.63% (+0.29)	―
Jul 12, 2023	2023 (Q2)	-0.25 / -0.41	-0.96	57.81% (+0.55)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

THTX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 09, 2025	$3.14	$3.14	0.00%
Apr 09, 2025	$1.55	$1.42	-8.39%
Feb 26, 2025	$1.82	$1.60	-12.09%
Oct 10, 2024	$1.22	$1.26	+3.28%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Theratechnologies Inc (THTX) report earnings?

Theratechnologies Inc (THTX) is schdueled to report earning on Oct 09, 2025, TBA (Confirmed).

What is Theratechnologies Inc (THTX) earnings time?

Theratechnologies Inc (THTX) earnings time is at Oct 09, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is THTX EPS forecast?

THTX EPS forecast for the fiscal quarter 2025 (Q3) is 0.01.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing